Project Grant R01HL167716
Award Date
8/1/24
Completion Date
7/31/28
Dollars Obligated
$601K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,061,189.00 to the Regents of the University of Michigan to conduct research on immune crosstalk in lung injury and fibrosis. The primary objectives are to study epithelial regulation of fibrosis and innate immunity against bacterial infections in the lungs, as well as test delivery of targeted therapies using nanoparticles. The...
This federal Project Grant award of $645,450 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of liver kinase B1 (LKB1) in decreased angiogenesis associated with bronchopulmonary dysplasia (BPD). The key objectives are to determine how hyperoxia exposure decreases LKB1-dependent signaling and mitochondrial biogenesis, and to examine the impact of decreased LKB1-AMPK signaling on...
This $2,070,206 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a long-term study on the genetic and physiological underpinnings of respiratory diseases in premature infants. The primary goal is to characterize distinct "endotypes" of bronchopulmonary dysplasia (BPD) that can predict long-term respiratory outcomes, in order to develop targeted, mechanism-based interventions. The...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $171,095 to the University of Alabama at Birmingham (UAB) from August 15, 2024 to July 31, 2029. The grant supports research to test the hypothesis that chorioamnionitis, a common cause of preterm birth, induces specific alterations of the fetal immune system via the IRAK1 pathway, resulting in lung parenchymal and vascular...
This $163,080 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to study the regulatory T cell (Treg) response in children with severe viral pneumonia. The grant supports research to determine if Treg cells have impaired reparative functions during severe viral pneumonia in children, assess how the lung microenvironment affects Treg pro-recovery functions, and identify Treg transcriptional...
This $586,021 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to establish patient-reported outcome measures to refine risk stratification and identify barriers to care for preterm infants with bronchopulmonary dysplasia (BPD). The key products will be: 1) a novel BPD-specific respiratory symptom measure to track symptom trajectories, and 2) parent-reported measures of barriers to care that...
This $651,019 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research at the University of Michigan to investigate the mechanisms underlying dysfunctional epithelial repair in pulmonary fibrosis. The research aims to identify factors that drive aberrant epithelial cell states, determine the impact of hypoxia-inducible factor (HIF) signaling on impairing alveolar repair, and investigate...
This Project Grant award of $798,958 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to understand the molecular mechanisms linking acute lung injury after transplantation to the development of chronic lung allograft dysfunction. The research will be conducted by Northwestern University and aims to determine whether activation of the integrated stress response in the airway and alveolar epithelium...
This federal Project Grant award of $915,924 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research focused on understanding how disruptions to early-life gut microbiome colonization can impair the development and function of key lung immune and epithelial cells. The research aims to elucidate how these microbiome-driven changes contribute to increased susceptibility to respiratory infections and the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $124,536 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the protective role of B cells in hyperoxic lung injury. The research aims to characterize the dynamics of B cell responses during hyperoxia and examine the protective impacts of B cell supplementation, as well as...